Savara

NSQ:SVRA · US8051111016

BiotechnologySmall

360° View

Value58

Price/Sales46

Price/Earnings76

Price/Book3

Dividend Yield—

Growth92

Revenue Growth—

Profit Growth60

Capital Growth93

TSR 52w78

Safety45

Leverage34

Liquidity64

Refinancing55

Combined67

Sentiment57

Analyst Opinions45

Pro Holdings45

Opinion Changes50

Market Pulse95

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Employees91

Websitesavarapharma.com

ISINUS8051111016

Last UpdateApr 2, 2026

Index & Theme

Chronic DiseasesHealth DiagnosticsPulmonologyImmunologyRespiratoryBiopharmaBiotechnologyPharmaceutical

Description

Savara Inc. (Savara) is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The company’s sole program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an investigational inhaled biologic, specifically a…

Analysis

Savara's 360° View rank of 71 places it above its peer average — better than 71% of its true peers.

It's a growth standout (92) and reasonably valued (58). On safety it is carrying more balance-sheet risk (45), and the market shows favorable sentiment (57). Taken together, its Combined rank of 67 reads as above its peer average.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Savara with its peers

Greenwich Lifesciences

NAQ:GLSI

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Replimune Group

NSQ:REPL

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Syndax Pharmaceuticals

NSQ:SNDX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Kyverna Therapeutics

NSQ:KYTX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Taysha Gene Therapies

NSQ:TSHA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Atea Pharmaceuticals

NSQ:AVIR

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →